Clinical Trial Update: Model-based Dose Versus Empirical Dose of Piperacillin/Tazobactam in Preterm Neonates With Late-onset Sepsis. [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial comparing model-based dosing versus empirical dosing of piperacillin/tazobactam in preterm neonates with late-onset sepsis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Late-onset Neonatal Sepsis

Drugs mentioned

• Piperacillin/tazobactam (Piperacillin/tazobactam)

Snippet

Sponsor: Shandong University | Conditions: Late-Onset Neonatal Sepsis | Phase 4 | Status: UNKNOWN